MacroGenics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
MacroGenics (Nasdaq: MGNX), a biopharmaceutical company specializing in cancer treatment through monoclonal antibody-based therapeutics, has announced its participation in three major investor conferences in March 2025:
- TD Cowen 45th Annual Healthcare Conference in Boston - CEO Scott Koenig will lead a fireside chat on March 5 at 10:30am ET
- Leerink Partners 2025 Global Healthcare Conference in Miami - Fireside chat scheduled for March 11 at 11:20am ET
- Barclays 27th Global Healthcare Conference in Miami - Presentation set for March 12 at 2:00pm ET
The company will conduct one-on-one meetings at all events. Webcasts will be available on MacroGenics' website under the Investor Relations section, with 30-day replay access.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MGNX declined 3.61%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March:
- TD Cowen 45th Annual Healthcare Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Wednesday, March 5, 2025, at 10:30am ET. MacroGenics’ management will also participate in one-on-one meetings.
- Leerink Partners 2025 Global Healthcare Conference (Miami). Dr. Koenig will participate in a fireside chat on Tuesday, March 11, 2025, at 11:20am ET. MacroGenics’ management will also participate in one-on-one meetings.
- Barclays 27th Global Healthcare Conference (Miami). Dr. Koenig will participate in a fireside chat on Wednesday, March 12, 2025, at 2:00pm ET. MacroGenics’ management will also participate in one-on-one meetings.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
FAQ
When is MacroGenics (MGNX) presenting at the TD Cowen Healthcare Conference in March 2025?
How long will the MGNX conference webcasts be available for replay?
Which investor conferences is MacroGenics (MGNX) attending in Miami during March 2025?
Where can investors access MacroGenics' (MGNX) conference presentation webcasts?
What type of meetings will MacroGenics (MGNX) management conduct at these conferences?
